ADVB earnings analysis
What we found in ADVB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Advanced Biomed (ADVB) experienced a notable decrease in losses for the three-month period ending March 31, 2026, reporting a net loss of $489,000 compared to a loss of $1.38 million for the same period in the prior year. The improvement in net loss was primarily attributed to a reduction in general and administrative expenses and gains from currency exchange. The company reported significant operating expenses with R&D costs rising 11% year-over-year.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Reduced Net Loss
- Net loss decreased by $894,932, from $1,383,874 in Q1 2025 to $489,942 in Q1 2026.
- Improved Other Income
- Other income turned positive to $31,006 in Q1 2026 from a loss of $629,992 in Q1 2025.
- Lower Operating Expenses
- Total operating expenses fell by $47,671 or 8% year-over-year, from $567,507 in Q1 2025 to $519,836 in Q1 2026.
- Positive Transition to Income
- For the nine-month period, the company reported a net income of $5,982,078, a $8,539,436 improvement from a loss of $2,557,358 in the previous year.
- Working Capital Increase
- Working capital increased to $9,100,625 as of March 31, 2026, from $3,143,443 on June 30, 2025.
- Cash Position Maintained
- The company reported cash of $2,602,697 as of March 31, 2026, indicating liquidity to support operations.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Cash Burn
- Operating cash flow was negative at $1,363,675 for the nine months ended March 31, 2026, though an improvement from $4,281,093 in the prior year.
- Regulatory Approval Dependency
- The company has yet to generate revenue and relies on regulatory approvals for future sales of products.
- Liquidity Risk Noted
- Management expressed substantial doubt about the company's ability to continue as a going concern without additional financing.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $6.2
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ADVB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever